CoChat

Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

Open access
Lapitz, Ainhoa, Azkargorta, Mikel, Milkiewicz, Piotr, Olaizola, Paula, Zhuravleva, Ekaterina, Grimsrud, Marit M., Schramm, Christoph, Arbelaiz, Ander, O'Rourke, Colm J., La Casta, Adelaida, Milkiewicz, Malgorzata, Pastor, Tania, Vesterhus, Mette, Jimenez-Agüero, Raul, Dill, Michael T., Lamarca, Angela, Valle, Juan W., Macias, Rocio I.R., Izquierdo-Sanchez, Laura, Pérez Castaño, Ylenia, Caballero-Camino, Francisco Javier, Riaño, Ioana, Krawczyk, Marcin, Ibarra, Cesar, Bustamante, Javier, Nova-Camacho, Luiz M., Falcon-Perez, Juan M., Elortza, Felix, Perugorria, Maria J., Andersen, Jesper B., Bujanda, Luis, Karlsen, Tom H., Folseraas, Trine, Rodrigues, Pedro M., Banales, Jesus M. · 2023 · Journal of Hepatology
Cited by 184

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

•Circulating EV-proteins allow for CCA risk prediction, early and differential (vs. HCC) diagnosis, and prognostication.•Serum CRP/FIBRINOGEN/FRIL levels discriminated patients with early-stage PSC-CCA from those with PSC.•Most pan-CCA biomarkers are mainly expressed in malignant cholangiocytes within human CCA tumours.•Serum CRP/FIBRINOGEN/FRIL/PIGR levels predict CCA development in patients with PSC before radiological tumour evidence.•The abundance of EV-proteins COMP/GNAI2/CFAI and ACTN1/MYCT1/PF4V independently predict patients’ overall survival. Background & AimsCholangiocarcinoma (CCA), heterogeneous biliary tumours with dismal prognosis, lacks accurate early diagnostic methods especially important for individuals at high-risk (i.e. those with primary sclerosing cholangitis [PSC]). Here, we searched for protein biomarkers in serum extracellular vesicles (EVs).MethodsEVs from patients with isolated PSC (n = 45), concomitant PSC-CCA (n = 44), PSC who developed CCA during follow-up (PSC to CCA; n = 25), CCAs from non-PSC aetiology (n = 56), and hepatocellular carcinoma (n = 34) and healthy individuals (n = 56) were characterised by mass spectrometry. Diagnostic biomarkers for PSC-CCA, non-PSC CCA, or CCAs regardless of aetiology (Pan-CCAs) were defined and validated by ELISA. Their expression was evaluated in CCA tumours at a single-cell level. Prognostic EV biomarkers for CCA were investigated.ResultsHigh-throughput proteomics of EVs identified diagnostic biomarkers for PSC-CCA, non-PSC CCA, or Pan-CCA, and for the differential diagnosis of intrahepatic CCA and hepatocellular carcinoma, which were cross-validated by ELISA using total serum. Machine learning-based algorithms disclosed CRP/FIBRINOGEN/FRIL for the diagnosis of PSC-CCA (local disease [LD]) vs. isolated PSC (AUC = 0.947; odds ratio [OR] =36.9) and, combined with carbohydrate antigen 19-9, overpowers carbohydrate antigen 19-9 alone. CRP/PIGR/VWF allowed the diagnosis of LD non-PSC CCAs vs. healthy individuals (AUC = 0.992; OR = 387.5). It is noteworthy that CRP/FRIL accurately diagnosed LD Pan-CCA (AUC = 0.941; OR = 89.4). Levels of CRP/FIBRINOGEN/FRIL/PIGR showed predictive capacity for CCA development in PSC before clinical evidence of malignancy. Multi-organ transcriptomic analysis revealed that serum EV biomarkers were mostly expressed in hepatobiliary tissues, and single-cell RNA sequencing and immunofluorescence analysis of CCA tumours showed their presence mainly in malignant cholangiocytes. Multivariable analysis unveiled EV prognostic biomarkers, with COMP/GNAI2/CFAI and ACTN1/MYCT1/PF4V associated negatively and positively with patients’ survival, respectively.ConclusionsSerum EVs contain protein biomarkers for the prediction, early diagnosis, and prognostication of CCA that are detectable using total serum, representing a tumour cell-derived liquid biopsy tool for personalised medicine.Impact and implicationsThe accuracy of current imaging tests and circulating tumour biomarkers for cholangiocarcinoma (CCA) diagnosis is far from satisfactory. Most CCAs are considered sporadic, although up to 20% of patients with primary sclerosing cholangitis (PSC) develop CCA during their lifetime, constituting a major cause of PSC-related death. This international study has proposed protein-based and aetiology-related logistic models with predictive, diagnostic, or prognostic capacities by combining two to four circulating protein biomarkers, moving a step forward into personalised medicine. These novel liquid biopsy tools may allow the (i) easy and non-invasive diagnosis of sporadic CCAs, (ii) identification of patients with PSC with higher risk for CCA development, (iii) establishment of cost-effective surveillance programmes for the early detection of CCA in high-risk populations (e.g. PSC), and (iv) prognostic stratification of patients with CCA, which, altogether, may increase the number of cases eligible for potentially curative options or to receive more successful treatments, decreasing CCA-related mortality. Cholangiocarcinoma (CCA), heterogeneous biliary tumours with dismal prognosis, lacks accurate early diagnostic methods especially important for individuals at high-risk (i.e. those with primary sclerosing cholangitis [PSC]). Here, we searched for protein biomarkers in serum extracellular vesicles (EVs). EVs from patients with isolated PSC (n = 45), concomitant PSC-CCA (n = 44), PSC who developed CCA during follow-up (PSC to CCA; n = 25), CCAs from non-PSC aetiology (n = 56), and hepatocellular carcinoma (n = 34) and healthy individuals (n = 56) were characterised by mass spectrometry. Diagnostic biomarkers for PSC-CCA, non-PSC CCA, or CCAs regardless of aetiology (Pan-CCAs) were defined and validated by ELISA. Their expression was evaluated in CCA tumours at a single-cell level. Prognostic EV biomarkers for CCA were investigated. High-throughput proteomics of EVs identified diagnostic biomarkers for PSC-CCA, non-PSC CCA, or Pan-CCA,

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2023.02.027

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 184

Metadata

Authors
Lapitz, A., Azkargorta, M., Milkiewicz, P., Olaizola, P., Zhuravleva, E., Grimsrud, M. M., Schramm, C., Arbelaiz, A., O'Rourke, C. J., La Casta, A., Milkiewicz, M., Pastor, T., Vesterhus, M., Jimenez-Agüero, R., Dill, M. T., Lamarca, A., Valle, J. W., Macias, R. I. R., Izquierdo-Sanchez, L., Pérez Castaño, Y., Caballero-Camino, F. J., Riaño, I., Krawczyk, M., Ibarra, C., Bustamante, J., Nova-Camacho, L. M., Falcon-Perez, J. M., Elortza, F., Perugorria, M. J., Andersen, J. B., Bujanda, L., Karlsen, T. H., Folseraas, T., Rodrigues, P. M., & Banales, J. M.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2023-07
Volume
79
Issue
1
Pages
93-108
ISSN
0168-8278 (ISSN-L)
OpenAlex
W4322724394
Cited by
184
References
6
FWCI
43.88
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma. https://app.cochat.ai/papers/10.1016/j.jhep.2023.02.027
The paper
Lapitz, A., Azkargorta, M., Milkiewicz, P., Olaizola, P., Zhuravleva, E., Grimsrud, M. M., Schramm, C., Arbelaiz, A., O'Rourke, C. J., La Casta, A., Milkiewicz, M., Pastor, T., Vesterhus, M., Jimenez-Agüero, R., Dill, M. T., Lamarca, A., Valle, J. W., Macias, R. I. R., Izquierdo-Sanchez, L., . . . Banales, J. M. (2023). Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2023.02.027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.